Objectives: To analyse the emergence of resistant viruses in patients failing darunavir monotherapy, including minority species, and to investigate the impact of baseline reverse transcriptase (RT), protease (PR) and gag resistance mutations on virological failure (VF) occurrence.
Introduction
Boosted protease inhibitor (PI) monotherapy has been proposed to be an antiretroviral option to avoid adverse effects related to the use of nucleosides while maintaining viral suppression for a majority of patients 1 -4 and to decrease the cost of treatment. In this context of simplification, different strategies of boosted PI monotherapy have been evaluated. 2, 4 Darunavir/ritonavir has been evaluated for use in these simplification strategies on the basis of its virological potency and high barrier to the development of resistance. 1, 3 One of the issues raised by PI monotherapy is the risk of drug resistance emergence in the case of virological failure (VF). Indeed, several trials have investigated resistance in monotherapy strategies at initiation 5 and in switch strategy, 6, 7 but few have studied minority species. The selection of PI resistance during single-drug maintenance therapy with lopinavir/ritonavir in the previously mentioned randomized studies was comparable to that observed during lopinavir/ritonavir-based triple therapy, in some cases with the selection of major PI resistance mutations. 8 -10 Concerning the impact of baseline mutations on the occurrence of VF, genomic regions other than protease (PR) might be involved in PI resistance, especially the PR gag and gag -pol cleavage sites. Several studies have shown that gag cleavage site mutations might influence the virological outcome of a PI-based regimen. 11 -14 We realized the pre-specified analyses of resistance of the MONOI trial, a 96-week, multicentre, randomized open-label trial with a primary endpoint at week 48 (W48). 3 Our objectives were both to look at the possible emergence of resistant viruses in patients failing darunavir monotherapy, including minority species, and to investigate the impact of baseline reverse transcriptase (RT), PR and gag resistance mutations found in DNA on subsequent VF.
Patients and methods

Study population
Overall, 225 HIV-1-infected patients were randomized in the MONOI trial (113 in the triple therapy arm and 112 in the monotherapy arm). The study definition of VF was two plasma HIV-1 viral loads .400 copies/ mL at least 2 weeks apart.
Ethics
The present study was carried out in accordance with the Declaration of Helsinki and was approved by the Comité de Protection des Personnes of Pitié Salpêtrière Hospital, Paris, France. All patients gave written informed consent to the collection of data.
Genotypic resistance tests
The resistance analyses were pre-specified in the original study. Genotypic resistance tests were performed for all patients presenting an HIV-1 RNA level .50 copies/mL that was confirmed in a second sample at least 2 weeks later.
Bulk sequences of the PR and RT genes at baseline (on DNA) and at the time of VF (on RNA) were determined in each laboratory using the Agence Nationale de Recherche sur le Sida et les Hépatites virales (ANRS) consensus technique primer sequences described at http://www. hivfrenchresistance.org. Darunavir resistance mutations (V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, L89V) were identified from the International AIDS Society-USA resistance testing panel. 15 At baseline on DNA, a gag-PR region of 323 bp, including the end of NC, p1/TFP and p6/p6pol, was amplified as described in an earlier article. 16 We focused on specific substitutions documented in the literature: 431, 436, 437, 441 and 449 residues in the gag and gag-pol open reading frames. 11, 12, 14, 16, 17 Differences in the frequency of baseline amino acids in the sequence compared with those in the HXB2 reference strain for these positions and the presence of insertions or deletions in this region were studied according to the VF using Fisher's exact test.
PR clonal analyses
In order to assess the presence of darunavir-resistant variants more sensitively, we performed PR gene clonal analysis on plasma samples of the nine patients who experienced VF as defined in the trial (two plasma HIV-1 viral loads .400 copies/mL at least 2 weeks apart). Purified PCR products were directly sequenced for bulk genotyping, some of which were cloned into the plasmid vector pCR Kit, Invitrogen, Carlsbad, CA, USA). Recombinant plasmid DNA was transformed into One Shot TOP10 chemically competent Escherichia coli; transformants were grown on ampicillin plates. Cloned DNA was re-amplified by PCR for sequencing. Fifty clones were sequenced for each sample. The PR gene was sequenced using a cycle sequencing reaction with the BigDye Terminator Kit (Applied Biosystems, Foster City, CA, USA). Sequences were analysed using SeqScape software.
Determination of darunavir plasma concentration
Steady-state minimal plasma concentrations of darunavir (12 or 24 h after the last drug intake according to a twice-or once-daily regimen) were determined using ultra-performance liquid chromatography with tandem mass spectrometry/mass spectrometry (UPLC -MS/MS) method (Acquity UPLC w -Acquity TQD w ) after sample extraction (limit of quantification 5 ng/mL) as previously described. 18 Nine samples were collected between day 0 (D0) and W48 (D0, W4, W8, W12, W16, W24, W32, W40 and W48) and six between W56 and W96 (W56, W64, W72, W80, W88 and W96). Darunavir plasma concentrations are presented as median (IQR) values and interpreted regarding the previously published data available in twice-and once-daily regimens. In the ARTEMIS study median darunavir C 24 was 2041 ng/mL and in the ODIN trial the median minimum concentration (C min ) was 1896 ng/mL for darunavir/ritonavir once daily and 3197 ng/mL for darunavir/ritonavir twice daily. 19, 20 Results Baseline characteristics of patients are presented in Table 1 . At baseline, sequences of the PR, RT and gag region genes were determined in DNA for 182 patients. The baseline genotype in DNA showed that the mean number of thymidine analogue mutations was 0.24, and the mean number of nucleoside Resistant minority species on darunavir/ritonavir monotherapy 1471 JAC reverse transcriptase inhibitor (NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations was 0.39 and 0.14, respectively; the mean number of primary PI resistance mutations was 0.08 (according to the IAS list of December 2010). For the gag region, we studied specific known substitutions using the gag and gag -pol open reading frames. Concerning gag mutations for the gag reading frame, frequencies of Y441H/N/S were 77%, 4% and 6%, respectively; frequencies of L449F/I/P were 2%, 2% and 13%, respectively. For the gag -pol reading frame the frequency of D437N was 60%, the frequencies of L441P/Q were 80% and 6%, respectively, and the frequency of S449P was 23%. There was no association between the presence of mutations in RT, PR and gag genes in DNA and VF or the occurrence of two consecutive HIV-1 viral loads .50 copies/mL.
To further characterize the selection of mutations in the case of VF, we performed genotype testing on RNA. For all patients with two plasma HIV-1 RNA .50 copies/mL at least 2 weeks apart, we obtained 47 bulk sequences and none presented a darunavir-associated resistance mutation. Among the 225 HIV-1-infected patients enrolled in the MONOI trial, 9 experienced VF (defined as two HIV-1 RNA values .400 copies/mL) over the 96 weeks of the study, including 5 patients in the darunavir/ritonavir monotherapy arm and 4 in the tritherapy arm (Table 2) . Among these failures, three occurred between D0 and W48 (twice-daily regimen) and six between W56 and W96 (once-daily regimen). One bulk sequence of Patient 1 presented a darunavir mutation V11I at VF, but this mutation was present prior to study entry in the RNA and in the baseline DNA Lambert-Niclot et al.
genotype. Clonal analysis of the PR region at VF was successfully performed in the nine failures, with 50 clones obtained for each patient. There was no selection of minority variants with darunavir resistance mutations except in Patient 2. Among the 50 clones obtained at failure for this patient, one harboured a V32I mutation, one an I47V mutation and one an I50V mutation. These mutations were not present in the RNA genotype prior to baseline or in the DNA genotype at baseline. This patient was in the darunavir/ritonavir monotherapy arm and his median darunavir C min between D0 and VF was adequate (2278 ng/mL), though he reported treatment discontinuation a few weeks before failure. After a good virological response, this patient presented VF at W40 with a plasma HIV-1 viral load of 1792 copies/mL. He had never received fosamprenavir-based therapy, which could have explained the selection of these mutations. After W48, he was switched to atazanavir/ritonavir plus tenofovir/emtricitabine with subsequent viral re-suppression. Finally, we performed clonal analysis of the gag region at VF for the nine patients and we did not find any selection of minority variants of specific mutations whatever the reading frame. Among the nine patients with VF, five had a median darunavir C min prior to VF below the expected C min in the corresponding regimen: Patient 1 (1075 ng/mL) on darunavir twice a day and Patients 5 (,5 ng/mL), 6 (1309 ng/mL), 8 (418 ng/mL) and 9 (942 ng/mL) on darunavir once a day. Except for Patient 5, most likely poorly adherent to therapy, all patients had darunavir C min above the darunavir half-maximal effective concentration (EC 50 ) corrected for protein binding of wild-type HIV-1 ( 55 ng/mL). 20 The four remaining patients had adequate median darunavir C min before experiencing VF.
Discussion
In the MONOI trial, where a strategy of darunavir monotherapy was compared with darunavir-based triple therapy, no darunavir-associated resistance mutations were selected in the nine patients, either in the monotherapy arm or in the triple darunavir therapy arm, who experienced VF using standard population sequencing at failure. The investigation of minority species in a darunavir/ritonavir monotherapy switch strategy showed the presence of minority variants harbouring darunavir resistance mutations (variant with V32I, one with I47V and one with I50V) in one patient failing darunavir/ritonavir monotherapy.
There have been several studies of resistance in PI monotherapy using a switch strategy. In the OK trial, which compared lopinavir/ritonavir monotherapy versus continuation of lopinavir/ritonavir and two NRTIs, only one patient had a minor PI resistance mutation that was not found in a pre-therapeutic sample. In the OK04 trial, based on the same protocol, the incidence of PI resistance was very low. 10 Indeed, two of the six patients who had VF had major PI resistance mutations, but pre-therapeutic samples were not available.
In the MONET trial of darunavir/ritonavir with or without nucleoside analogues, the prevalence of resistance to PIs was low. 7 Genotypes were available for only 54% of VFs (38/70 patients). There was one patient in each treatment arm who showed genotypic resistance to PI or NRTIs. The patient in the monotherapy arm had a single darunavir mutation (L33F), but it is unknown whether this mutation was present before the trial. In our study VFs increased over time, but these failures did not seem to be related to the transition from twice-daily to once-daily regimens.
Here, there was no association between mutations in the RT, PR and gag genes in DNA and VF, but the frequencies of mutations were very low. These low frequencies are in accordance with previous studies showing that the use of proviral DNA for standard genotyping is less informative than taking account of the entire history of RNA genotyping results. 21 In this study the patients did not have PI VF before the trial and all samples were not available to permit the study of RNA genotypes.
In conclusion, in patients showing failure on darunavir/ ritonavir monotherapy, we found a very low prevalence of PI resistance, which is consistent with other PI monotherapy studies. 7, 10 In all patients with two plasma HIV-1 RNA levels .50 copies/mL at least 2 weeks apart, bulk sequencing did not show any selection of darunavir resistance mutations. Therapeutic resumption of the initial two NRTIs, change of PI or reintroduction of treatment when treatment discontinuation led to HIV-1 RNA ,50 copies/mL. However, one of the nine patients with two plasma HIV-1 RNA levels .400 copies/mL at least 2 weeks apart presented minority variants plus darunavir resistance mutations at positions 32, 47 and 50 that were not detectable using standard genotype testing.
